Remove Bioinformatics Remove Research Remove Small Molecule
article thumbnail

From siloed data to breakthroughs: multimodal AI in drug discovery

Drug Target Review

Unimodality does not allow for mixing data: cell data, images, molecular data, clinical data records, small molecule descriptors, ADME Tox data, transcriptomic data, text-based drug and disease representations, clinical trial protocols, publications and patent data, etc.

Drugs 64
article thumbnail

Unlocking the potential of natural products in drug discovery

Drug Target Review

Between 2000 and 2020, approximately 30 percent of the newly introduced small molecule drugs were derived from natural products. 1 Researchers have also observed a correlation between greater translatability of natural products and increased progression through clinical trials.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Breakthrough in Functional Annotation with HiFi-NN

Nvidia Developer: Drug Discovery

The applications of artificial intelligence for enzyme generation is an exciting field of research with direct applications in the life sciences. Improved methods for functional annotation are a vital component in enzyme research, enabling the identification and characterization of the functions of newly discovered enzymes.

Science 107
article thumbnail

Biochemical assays and deep cyclic inhibition in cancer treatment

Drug Target Review

Many cell lines used in pancreatic cancer research, for example, are generally not genetically aligned with most patients in the clinic. Once a new drug target is identified, a proprietary deep learning artificial intelligence (AI) platform we call Fluency can rapidly identify small molecules that selectively bind to a target of interest.

article thumbnail

Reaching cruising altitude: New discovery tools to target RNA

Dark Matter Blog

The majority of small molecule drugs induce their therapeutic effects by seeking out and binding to their intended target while avoiding most other molecules in the dense milieu of the cell interior. Our overall mission at Arrakis is to expand the set of “druggable” targets for small-molecule medicines to include RNA.

RNA 52
article thumbnail

AI in Drug Discovery - A Highly Opinionated Literature Review (Part II)

Practical Cheminformatics

Aside from some very brief demos on code generation and literature searches, mentions of LLM applications in preclinical research were scarce. A preprint from Microsoft AI Research provided a broad catalog of potential LLM applications in the physical and life sciences. Most of the drug discovery examples were underwhelming.

Drugs 136
article thumbnail

AI At The Frontier: Empowering Early Career Professionals In Drug Discovery

Elrig

With a background in Bioinformatics and Computational Biology, she has a keen interest in using technology to solve problems in healthcare and medicine. Miguel Gancedo Rodrigo Miguel Gancedo Rodrigo Research Investigator, Isomorphic Labs My name is Miguel, and I’m from Murcia, Spain.